IU training prog. in molecular physiology and clinical mechanisms of lung disease
IU培训计划。
基本信息
- 批准号:7817138
- 负责人:
- 金额:$ 19.17万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2009
- 资助国家:美国
- 起止时间:2009-05-01 至 2014-04-30
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
DESCRIPTION (provided by applicant): This T-32 Training application is anchored within the Indiana University School of Medicine, the principal School of the Indiana University Purdue University at Indianapolis (lUPUI). The proposed training program in Lung Immunobiology is provided by a multidisciplinary, highly collaborative group of established investigators and highly qualified and dedicated mentors. We have included in the training program classical elements of basic and clinical-translational, research, adding on developing novel technologies. These research skills will enable our trainees to accelerate the advancements in lung research and close the gaps in knowledge that prevented for so many decades the development of phenotypic characterization, effective preventive intervention, and disease- modifying or even curative druts for most patients with lung disease. Being led by Program Director who is a renowned physician scientist and experienced mentor who himself is a minority, and having direct support from an experienced Minority Advisory Board, this application demonstrates our commitment to the development of a successful training program for under-represented and minority scientists. The Program Director will obtain continuous advise and feedback regarding the operation of the Training Grant from several internal and one external committee, composed of leaders in academic medicine If funded, this program will provide the only research training program of pulmonary physicians and scientists in the state of Indiana, which has one of the highest incidence of chronic lung diseases in the country.
说明(由申请人提供):此 T-32 培训应用程序位于印第安纳大学医学院,该医学院是印第安纳大学印第安纳波利斯分校普渡大学 (lUPUI) 的主要学院。拟议的肺免疫生物学培训计划由一个多学科、高度协作的小组提供,该小组由成熟的研究人员和高素质且敬业的导师组成。我们在培训计划中纳入了基础和临床转化、研究的经典要素,并增加了新技术的开发。这些研究技能将使我们的学员能够加速肺部研究的进展,并缩小知识差距,这些差距几十年来阻碍了大多数肺部疾病患者的表型特征、有效的预防干预以及疾病改变甚至治疗药物的发展。该申请由项目总监领导,他是一位著名的医学科学家和经验丰富的导师,他本人也是少数族裔,并得到经验丰富的少数族裔咨询委员会的直接支持,这表明了我们致力于为代表性不足和少数族裔科学家开发成功的培训计划。项目主任将从几个内部和一个外部委员会获得有关培训补助金运作的持续建议和反馈,该委员会由学术医学领域的领导者组成。如果获得资助,该项目将为印第安纳州提供唯一的肺科医生和科学家研究培训项目,印第安纳州是美国慢性肺病发病率最高的州之一。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
David S Wilkes其他文献
A 46-Year-Old Man With Excruciating Shoulder Pain
- DOI:
10.1378/chest.127.3.1039 - 发表时间:
2005-03-01 - 期刊:
- 影响因子:
- 作者:
Eric J Olafsson;Tallal Zeni;David S Wilkes - 通讯作者:
David S Wilkes
David S Wilkes的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('David S Wilkes', 18)}}的其他基金
TH17 Autoimmunity to Type V Collagen in Heart and Lung Transplant
TH17 在心肺移植中对 V 型胶原的自身免疫
- 批准号:
8713903 - 财政年份:2010
- 资助金额:
$ 19.17万 - 项目类别:
IL-17A and anti-col (V) humoral immunity in lung allograft rejection
IL-17A 和抗 col (V) 体液免疫在肺同种异体移植排斥反应中的作用
- 批准号:
7810371 - 财政年份:2010
- 资助金额:
$ 19.17万 - 项目类别:
TH17 Autoimmunity to Type V Collagen in Heart and Lung Transplant
TH17 在心肺移植中对 V 型胶原的自身免疫
- 批准号:
8136215 - 财政年份:2010
- 资助金额:
$ 19.17万 - 项目类别:
TH17 Autoimmunity to Type V Collagen in Heart and Lung Transplant
TH17 在心肺移植中对 V 型胶原的自身免疫
- 批准号:
8317659 - 财政年份:2010
- 资助金额:
$ 19.17万 - 项目类别:
Renovation of the Wells Research Center for a Pediatric Phenotyping Core
威尔斯研究中心儿科表型分析核心的改造
- 批准号:
7935901 - 财政年份:2010
- 资助金额:
$ 19.17万 - 项目类别:
TH17 Autoimmunity to Type V Collagen in Heart and Lung Transplant
TH17 在心肺移植中对 V 型胶原的自身免疫
- 批准号:
8523761 - 财政年份:2010
- 资助金额:
$ 19.17万 - 项目类别:
TH17 Autoimmunity to Type V Collagen in Heart and Lung Transplant
TH17 在心肺移植中对 V 型胶原的自身免疫
- 批准号:
7765108 - 财政年份:2010
- 资助金额:
$ 19.17万 - 项目类别:
IU training prog. in molecular physiology and clinical mechanisms of lung disease
IU培训计划。
- 批准号:
7694656 - 财政年份:2009
- 资助金额:
$ 19.17万 - 项目类别:
IU training prog. in molecular physiology and clinical mechanisms of lung disease
IU培训计划。
- 批准号:
8065435 - 财政年份:2009
- 资助金额:
$ 19.17万 - 项目类别:
相似海外基金
CMKLR1-Targeted Molecular Imaging of Inflammation as a Precision Medicine Tool in Acute Lung Injury and Fibrotic Lung Diseases
CMKLR1 靶向炎症分子成像作为急性肺损伤和纤维化肺疾病的精准医学工具
- 批准号:
10733483 - 财政年份:2023
- 资助金额:
$ 19.17万 - 项目类别:
1/2 Prospective tReatment EffiCacy in IPF uSlng genOtype for Nac Selection (PRECISIONS) trial and Molecular Endophenotyping in Idiopathic Pulmonary Fibrosis and Interstitial Lung Diseases study
IPF 使用基因型进行 Nac 选择 (PRECISIONS) 试验和特发性肺纤维化和间质性肺疾病分子内表型分析研究中的 1/2 前瞻性治疗效果
- 批准号:
10385681 - 财政年份:2020
- 资助金额:
$ 19.17万 - 项目类别:
1/2 Prospective tReatment EffiCacy in IPF uSlng genOtype for Nac Selection (PRECISIONS) trial and Molecular Endophenotyping in Idiopathic Pulmonary Fibrosis and Interstitial Lung Diseases study
IPF 使用基因型进行 Nac 选择 (PRECISIONS) 试验和特发性肺纤维化和间质性肺疾病分子内表型分析研究中的 1/2 前瞻性治疗效果
- 批准号:
10618152 - 财政年份:2020
- 资助金额:
$ 19.17万 - 项目类别:
1/2 Prospective tReatment EffiCacy in IPF uSlng genOtype for Nac Selection (PRECISIONS) trial and Molecular Endophenotyping in Idiopathic Pulmonary Fibrosis and Interstitial Lung Diseases study
IPF 使用基因型进行 Nac 选择 (PRECISIONS) 试验和特发性肺纤维化和间质性肺疾病分子内表型分析研究中的 1/2 前瞻性治疗效果
- 批准号:
10026438 - 财政年份:2020
- 资助金额:
$ 19.17万 - 项目类别:
Prospective tReatment EffiCacy in IPF uSlng genOtype for Nac Selection (PRECISIONS) trial and Molecular Endophenotyping in Idiopathic Pulmonary Fibrosis and Interstitial Lung Diseases study
IPF 使用基因型进行 Nac 选择 (PRECISIONS) 试验和特发性肺纤维化和间质性肺疾病分子内表型研究的前瞻性治疗效果
- 批准号:
10596595 - 财政年份:2019
- 资助金额:
$ 19.17万 - 项目类别:
Prospective tReatment EffiCacy in IPF uSlng genOtype for Nac Selection (PRECISIONS) trial and Molecular Endophenotyping in Idiopathic Pulmonary Fibrosis and Interstitial Lung Diseases study
IPF 使用基因型进行 Nac 选择 (PRECISIONS) 试验和特发性肺纤维化和间质性肺疾病分子内表型研究的前瞻性治疗效果
- 批准号:
10385682 - 财政年份:2019
- 资助金额:
$ 19.17万 - 项目类别:
Prospective tReatment EffiCacy in IPF uSlng genOtype for Nac Selection (PRECISIONS) trial and Molecular Endophenotyping in Idiopathic Pulmonary Fibrosis and Interstitial Lung Diseases study
IPF 使用基因型进行 Nac 选择 (PRECISIONS) 试验和特发性肺纤维化和间质性肺疾病分子内表型研究的前瞻性治疗效果
- 批准号:
10021690 - 财政年份:2019
- 资助金额:
$ 19.17万 - 项目类别:
RLDC: Molecular Pathway-Driven Diagnostics & Therapeutics for Rare Lung Diseases
RLDC:分子途径驱动的诊断
- 批准号:
8765116 - 财政年份:2014
- 资助金额:
$ 19.17万 - 项目类别:
RLDC: Molecular Pathway-Driven Diagnostics & Therapeutics for Rare Lung Diseases
RLDC:分子途径驱动的诊断
- 批准号:
9140225 - 财政年份:2014
- 资助金额:
$ 19.17万 - 项目类别:
RLDC: Molecular Pathway-Driven Diagnostics & Therapeutics for Rare Lung Diseases
RLDC:分子途径驱动的诊断
- 批准号:
9114659 - 财政年份:2014
- 资助金额:
$ 19.17万 - 项目类别: